nongenital

Imiquimod (R 837) is an immune response modifier and a toll-like receptor 7 (TLR7) agonist with antiviral and antitumor effects. It is used in the study of external genital warts, perianal warts, cancer, and COVID-19, and is commonly employed to induce psoriasis models.

Imiquimod hydrochloride (R 837 hydrochloride) is a selective toll-like receptor 7 (TLR7) agonist and immune response modulator with antiviral and antitumor activities. It is used in the study of external genital warts, perianal warts, cancer, COVID-19, pemphigus foliaceus, skin cancer, and psoriasis, and is commonly employed to establish psoriasis models.

Imiquimod maleate (R 837 maleate) is a toll-like receptor 7 (TLR7) agonist and immune response modifier with antiviral and antitumor activities. It is used in the study of external genital warts, perianal warts, cancer, and COVID-19, and can induce psoriasis-like skin lesions in mice, commonly used to establish psoriasis models.

Imiquimod 2HCl is a toll-like receptor 7 (TLR7) agonist and immune modulator with antiviral and antitumor activities. It can be used to establish psoriasis-like mouse models and for the study of periorbital skin cancer, pemphigus foliaceus, and COVID-19.

Imiquimod (Standard) is the standard substance of Imiquimod, and it is applicable for quantitative analysis, quality control, and related research in biochemical experiments. Imiquimod (R 837) is an immune response modifier and a toll-like receptor 7 (TLR7) agonist with antiviral and antitumor effects. It is used in the study of external genital warts, perianal warts, cancer, and COVID-19, and is commonly employed to induce psoriasis models.

Imiquimod-D9 is the deuterated form of Imiquimod. Imiquimod (T0134) (R 837) functions as a toll-like receptor 7 (TLR7) agonist, serving as an immune response modifier. It demonstrates antiviral and antitumor effects in vivo and is applicable in research related to external genital and perianal warts, cancer, and COVID-19.